Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab IV vs SC Maintenance in Crohn's Disease
ChiCTR2200060604Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ustekinumab in Crohn's disease (2 arms), sponsored by Xijing Hospital. Primary endpoints: Clinical response rate, Clinical remission rate and 2 more. Started Apr 2022; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2200060604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060604.